Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ISBG Experiential marketing directly engages, invites, and encourages consumer interaction and brand participation.
While costly traditional advertising via radio, print, and television verbally and visually communicates product benefits, experiential marketing immerses consumers within the brand itself by engaging as many human senses as possible. In this way, experiential marketing can encompass a variety of of integrated strategies from individual event sampling to large-scale guerrilla marketing and product placement within the entertainment world. The goal of experiential marketing is to form a memorable and emotional connection between the consumer and the brand. When done effectively it generates customer loyalty and influences purchase decisions. Our goal is to integrate our brands with the social fabric of our markets, ensuring that our brands are visible in the right establishments and at the right events. ISBG will be actively launching and supporting our brands and aims to be a leader in experiential marketing.
$PMCB Research report explores the pancreatic cancer pipeline products, key players involved and enlists all their major and minor projects
WhaTech Channel: Medical Market Research
Published: 29 July 2016
Submitted by RNR Market Research. WhaTech Agency
News from RnR Market Research
Viewed: 257 times
https://www.whatech.com/market-research/medical/188106-research-report-explores-the-pancreatic-cancer-pipeline-products-key-players-involved-and-enlists-all-their-major-and-minor-projects
$PMCB Oncomed Pharmaceuticals Stumbles, But Pharmacyte Biotech Continues to Offer Hope in War on Pancreatic Cancer
Oncomed Pharmaceuticals Inc. (NASDAQ:OMED) just reiterated today how tough pancreatic cancer is to beat. Pharmacyte Biotech Inc. (OTCMKTS:PMCB) is also tough though, and continues to move forward with the cancer community's next big leap forward in the war on pancreatic cancer.
For fans and followers of Oncomed Pharmaceuticals Inc. (NASDAQ:OMED), the new trading week is getting started on the wrong foot. Although the company is going to continue on with this particular stage of the trial, the so-called ALPINE trial of it cancer immunology drug tarextumab as a therapy for pancreatic cancer doesn't look like it's going to meet its endpoint goal.
The announcement from OMED underscores just how tough pancreatic cancer is to beat; this is hardly the first instance of a well-known (and otherwise effective therapy) failing to do much good when it comes to treating the dreaded disease. Yet, the stumble for Oncomed Pharmaceuticals also puts a small biotech firm called Pharmacyte Biotech Inc. (OTCMKTS:PMCB), as it's developing a pancreatic cancer treatment option that just might be the next, long-awaited quantum leap for this particular sliver of the oncology world.
Just for the record, in the phase 2 ALPINE trial, Oncomed Pharmaceuticals observed a distinct lack of benefit -- no progress in terms of progression-free survival or overall survival rates -- compared to a placebo. Such results contrast with trials recently performed by Pharmacyte Biotech.
Pharmacyte Biotech is the developer of a biotechnology called Cell-in-a-Box(r). In simplest terms, Cell-in-a-Box(r) is a means of encapsulating live cells -- cells grown to perform a particular function -- and implanting these pinhead-sized capsules in the body to perform a specific medical purpose. The technology has many applications, but PharmaCyte Biotech is furthest along in its development of the idea as a means of treating pancreatic cancer.
In phase 2 trials, PharmaCyte has shown that catalyzing a prodrug form of cancer-fighting therapy ifosfamide in the bloodstream physically near the cancer-ridden pancreas maximizes the effectiveness while minimizing the dosage. Ergo, this approach has proven superior to activation of the drug in the liver.
While potent, ifosfamide can also cause significant side effects when taken at doses large enough to effectively fight cancer. That's because liver-activated ifosfamide must make it all the way through the entire circulatory system before it reaches the pancreas. Most of the drug never reaches the pancreatic tumor. By activating the drug in the leg, though, the activated ifosfamide only needs to travel a few inches to reach the pancreas. The end result is an impressive degree of efficacy at only one-third the normal intravenous dosage of ifosfamide.
In a phase 1/2 trial examining the benefit of the Cell-in-a-Box(r) activation of ifosfamide versus the results gemcitabine would be able to achieve alone, the Pharmacyte approach improved the median survival timeframe from 28 to 44 weeks. Equally impressive is the fact that the number of one-year survivors increased from 18% to 36% of the study's patients.
The initial goal of Pharmacyte Biotech and its Cell-in-a-Box was as a frontline treatment, where it performed very well relative to current first-effort therapies of gemcitabine or a combination of gemcitabine and Abraxane. As the study progressed, however, the company recognized the drug ifosfamide when activated by its Cell-in-a-Box platform could effectively meet a much bigger and perhaps much more lucrative unmet need... pancreatic cancer patients for whom gemcitabine or the combination of gemcitabine and Abraxane was no longer effectively shrinking a tumor (even if it had stopped its growth).
That's about 40% of the pancreatic cancer patient population completely up for grabs, so to speak, as there is no "good" solution. Pharmacyte Biotech may be about to change that.
The next step is a redesigned phase 2 trial. The trials had to be reworked when the company recognized it would be better off aiming at a slightly different target. The new plans are taking shape right now, however, and the new phase 2 trial should begin soon. It's a reason to be excited about PMCB.
I believe that it's soon time for me to revive this board
$PMCB PharmaCyte Biotech Management Interviewed to Discuss Key Aspects of New Pancreatic Cancer Clinical Trial Design
Source: GlobeNewswire Inc.
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the release of a recorded interview with Chief Executive Officer Kenneth L. Waggoner and Chief Operating Officer Dr. Gerald W. Crabtree that highlights the key aspects of PharmaCyte’s new pancreatic cancer clinical trial design.
Listen to the interview here: http://www.stockmarketmediagroup.com/wp-content/uploads/2015/10/PharmaCyte_Biotech_CEO_Interview.mp3
The interview walks the audience through PharmaCyte’s last three press releases that announce the change in its clinical trial design. In the interview, PharmaCyte’s Chief Executive Officer and Chief Operating Officer discuss PharmaCyte’s efforts to address an unmet medical need with PharmaCyte’s pancreatic cancer treatment, why the trial was moved to the United States under the direction of Translational Drug Development (TD2) and some of the specifics related to the new trial design.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®”. This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed.
PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells capable of converting an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and secrete insulin at levels in proportion to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com
Primary Logo
TSOI penny bound! Nice low float play, just 46 million. Makes huge moves when it gets some volume. 5 patents pending. .0087 x .01
$PMCB Armed With FDA Orphan Drug Status in the U.S., PharmaCyte Biotech Now Securing Europe for Pancreatic Cancer Treatment
Source: Marketwired
Armed With FDA Orphan Drug Status in the U.S., PharmaCyte Biotech Now Securing Europe for Pancreatic Cancer Treatment
BONITA, CA-(Marketwired - October 09, 2015) - The combination of PharmaCyte Biotech’s (OTCQB: PMCB) signature live-cell encapsulation technology, Cell-in-a-Box® with low doses of ifosfamide has already won the FDA's "Orphan Drug" status here in the U.S., and now it seems the company will also be awarded the “Orphan Designation” with the European Medicines Agency (EMA), which would guarantee 10 years of competition-free marketing when the pancreatic cancer treatment is approved.
In the world of biopharma, it doesn't take long for a company to copy or mimic a popular, successful drug. In fact, for some less-common diseases, the industry realizes that merely sharing the revenue generated by a small niche may not even be worth the effort, meaning those rare or difficult-to-treat diseases often go completely unaddressed. If all goes as planned for PharmaCyte and its novel pancreatic cancer treatment, not only does it stand to introduce a game-changing therapy to the market, it could be rewarded for its efforts with years of exclusive marketing rights in for its patented treatment.
In the U.S., the FDA has given PharmaCyte the Orphan Designation, which will give the company 7 years of marketing exclusivity when the company’s pancreatic cancer treatment is approved. Now, the company has hinted that it is close to securing the Orphan Designation with the EMA in Europe, which will offer PharmaCyte 10 years of marketing exclusivity when its treatment is approved.
PharmaCyte Biotech is the developer of a live-cell encapsulation platform biotechnology known as Cell-in-a-Box®. In simplest terms, Cell-in-a-Box is a means of encapsulating and implanting living cells into a patient's body where they can drive a specific therapeutic effect. In the case of PharmaCyte's pancreatic cancer therapy, these encapsulations (about the size of the head of a pin) contain cells that produce an enzyme, which activates a cancer-killing drug called ifosfamide.
The advantage of this method of drug-activation is pinpoint placement within the body.
Ifosfamide is usually converted to its cancer-killing form in the liver. It works, but the bulk of the drug gets "lost" before reaching the pancreatic tumor given the pancreas is the last organ on the circulatory system. By moving the “activation site” from the liver to the site of the tumor - by implanting about 300 of these pinhead-sized encapsulations at the site of the tumor - ifosfamide isn't converted into its useful form until the last possible moment, insuring maximum impact of the drug at a minimal dosage.
And, the company has already seen compelling results with this approach through the first part of its phase 1/2 trials.
In a test comparing the benefit of the Cell-in-a-Box delivery of ifosfamide versus historical results for the drug gemcitabine alone, the PharmaCyte approach improved the median survival time from 28 to 44 weeks. Equally impressive is the fact that the number of one-year survivors of the study's patients increased from 18% to 36%.
That was enough to get the FDA's attention, which has since granted the combination of Cell-in-a-Box and ifosfamide an "Orphan Drug" designation. Better yet, per Wednesday's news release, the company is in the process of securing the same Orphan Designation with the European Medicines Agency according to PharmaCyte CEO Kenneth L. Waggoner.
The FDA and other sovereign agencies created the Orphan Drug Designation as a means to encourage the development of treatments for rare diseases that may not otherwise be addressed by the industry. One of the more advantageous benefits of the Orphan Drug status is generous tax breaks, though the biggest upside may be multi-year marketing exclusivity. The FDA's marketing-exclusivity rights for its designated Orphan Drugs extend for 7 years after the drug is approved. The EMA's orphan drug program is similar, though it guarantees marketing exclusivity for a period of 10 years.
That's practically an eternity for a drug, during which time - if ifosfamide and Cell-in-a-Box are approved - PharmaCyte Biotech would continue to develop its biotechnology as a means of treating diabetes, and even brain cancer.
At stake is a piece of an underserved $2 billion pancreatic cancer market, a market that could prove very lucrative with the therapy's exclusive marketing rights being in place for several years after any approval.
The next step is the upcoming phase 2b clinical trial using Cell-in-a-Box® with low doses of the drug ifosfamide in hopes of providing patients with a treatment that meets a current unmet medical need in the treatment of advanced pancreatic cancer.
Read more articles and our research report on PharmaCyte Biotech atwww.smallcapnetwork.com.
About SmallCap Network
The SmallCap Network is an electronic publication committed to providing our readers with useful information on publicly traded companies. SmallCap Network sometimes contracts with third parties or publicly traded companies and receives compensation from them in the form of cash and sometimes restricted securities as payment for publishing information and opinion about the company and the trading market for their securities. Principals of the SmallCap Network may also purchase or sell securities of the companies in the open market from time to time. The positions that the SmallCap Network or its principals maintain in securities of the companies are disclosed here and should be considered in making an investment decision regarding companies mentioned on the SmallCap Network site. The SmallCap Network may be deemed to have a conflict of interest between its open market activity and positions in these securities and the timing of and opinions expressed in its publications concerning these companies. SmallCap Network has been compensated $10,000 and has been pledged a fee of $4,000 per month by a third party for market awareness and other advertising services on PMCB.
All statements and opinions expressed herein are those of the editors and staff of SmallCap Network and are subject to change without notice. The SmallCap Network maintains editorial control over its publications and the companies profiled therein do not have any editorial rights concerning the information published about them. No information contained in our website, e-mail communications or our publications should be considered as a solicitation to purchase or sell any of the securities mentioned. SmallCap Network, its principals or employees are not registered investment advisors or a registered securities broker dealer. We do not undertake or represent to make investment recommendations or to give advice pertaining to the purchase or sale of the securities mentioned in our web site, e-mail communications or publications. While we believe all sources of information provided by us and contained in our publication to be accurate and reliable, we cannot and do not guarantee the accuracy of information we received from third parties.
Furthermore, SmallCap Network has not independently verified such information provided within our publication. Readers are encouraged to do their own due diligence before investing in any securities mentioned in this article. Investing in securities is speculative and carries a high degree of risk. We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.finra.org. We also recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found athttp://www.sec.gov/consumer/cyberfr.htm.
Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site. The information found in this Newsletter is protected by the copyright laws of the United States and may not be copied, or reproduced in any way without the expressed, written consent of The SmallCap Network.
CONTACT INFORMATION
Contact:
SmallCap Network
customerservice@smallcapnetwork.com
$PMCB BarChart Trader's Cheat Sheet
http://www.barchart.com/cheatsheet.php?sym=PMCB
If I can get a lower entry for people on this board I'd be happy. Then shares pass into stronger more decent hands.
Thank you for the sharing your advice, Shaz :)
In all honesty the traders left today so folks might get a better entry than I did.
So time your entry folks. SNXG 52 high is 37 cents.
Nice post Shaz! Going to sticky :) $SNXG
Six reasons to buy SNXG
Two more PR's coming in the next month
1) Saying the acquisition of the mine is completed.
2) Saying they mine is up and running and they already say its profitable.
3) Makes the company instantly profitable
4) Low floater
5) 52 Week high 37 cents!!!!!
6) Two more PR's to come
http://www.otcmarkets.com/stock/SNXG/news/SunX-Energy-Announces-Acquisition-Proposal-for-Precious-Metal-Operations-in-Asia-?id=114475&b=y
See for yourselves it's all there in the press release from yesterday:
SunX Energy Announces Acquisition Proposal for Precious Metal Operations in Asia.
Las Vegas, NV. September 15th, 2015 --- SUNX Energy (OTC PINK:SNXG), Bill Schaefer CEO of the company would like to announce today that it has entered into an agreement to acquire precious metal mining and production operations in South East Asia with an investment platform comprising Indonesia and the Philippines.
The Company expects that the newly acquired operations will closed by the end of September, 2015
and be fully operational and profitable by October 2015.
In announcing the proposed acquisition, Mr. Schaefer, CEO of SunX Energy commented: I believe the fundamentals of this acquisition will build a very strong company with excellent opportunities……
You as well my friend.
You got it brother looks great have a nice evening!
TY sir! . $MSOA
Stickied Papa Bear! $MSOA
MSOA: check this out FOLKS!!:
108M OS! <<< >>> 21M FLOAT!! <<< >>> 2.5B COMMON SHARES CANCELLED!! <<< >>> 34M PREFERRED SHARES CANCELLED!! <<< >>> CLOSED AT .0017! UP 54% TODAY!!!! <<< >>> MORE GREEN ON TUESDAY!!! <<<
UAPC looks interesting, some solid traders there imo. gLTA.
$BLSP $0.023 big news today
Blue Sphere Corp. Announces Conversion of All Amounts Owing Under Convertible Debentures
CHARLOTTE, NC--(Marketwired - Sep 8, 2015) - Blue Sphere Corp. (OTCQB: BLSP) (the "Company" or "Blue Sphere"), a clean energy company that develops, manages and owns waste-to-energy projects, announced today that all amounts owing under the Company's issued and outstanding convertible debentures have been converted in full.
"We are pleased to announce that the Company's debt conversion program is complete and that all outstanding amounts have been converted in full. The Company's convertible debentures program commenced in August 2014 and peaked, in the aggregate, to $1.5 million. The complete conversion of our convertible debentures reflects our confidence in the short and long-term strength of Blue Sphere, as well as our continued commitment to optimizing shareholder returns" said Mr. Shlomi Palas, Chief Executive Officer of the Company.
Mr. Palas added that, "Blue Sphere has successfully funded and started construction of two large Waste-To-Energy facilities which are expected to deliver a total amount of $4.675 million in Development Fees to the Company during late 2015 and 2016. In addition, the Company was reimbursed $.545 million in project expenses during 2015 and is expecting to receive further reimbursement of $.640 million in equity working capital. The Company and its partners in the Charlotte, NC and Johnston, RI facilities are also negotiating the monetization of the Investment Tax Credit."
Mr. Palas continued, "Considering the meaningful performance of the Company during the past year and its stronger balance sheet, we feel that the Company's common stock is currently significantly undervalued and the Company will continue to focus on its Repurchase Program."
About Blue Sphere Corporation
Blue Sphere Corporation is a company in the cleantech sector as a waste-to-energy project integrator. Blue Sphere develops waste-to-energy and other renewable energy projects. The Company aspires to become a key player in the global waste-to-energy and renewable energy markets. For further information, please visit the Company's website: www.bluespherecorporate.com.
Forward-Looking Statements
This press release contains certain forward-looking statements (within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995), which are subject to risks and uncertainties and may change at any time. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors including, without limitation, (i) uncertainties regarding general economic and market conditions, (ii) uncertainties regarding changes in the Clean tech sector, (iii) uncertainties regarding implementation of the Company's business strategy, and (iv) other risk factors as outlined in the Company's periodic reports, as filed with the U.S. Securities and Exchange Commission. As such, there is no assurance that the initiatives described in this press release will be successfully implemented or meet expectations. Forward-looking statements in this document speak only as of the date on which such statements were made, and we undertake no obligation to update any such statements that may become untrue because of subsequent events.
Contact Information:
Stanley Wunderlich
Launchpad IR
1-800-625-2236
swunderlich@launchpadir.com
www.tacticalgrowthpartners.com
Copyright © 2015 Marketwired. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
$BLSP
$$IGEX$$ beginning of a huge movement underway, all the DD needed is being provided on a silver platter on the board. Ground floor opportunity.
$IGEX will test and likely (IMO) break the 200 Day MA @ $0.0043 tomorrow, watch for a big move into blue sky territory if that happens
Very nice, $ECDP BEAST! Watch $HCTI & $EVTI as well :)
LFAP Looking to be the next runner! Moving up today. A/S 300 million, O/S 214 million!
Awesome my man congratulations! Really happy for you guys, and so thankful the company followed through that's HUGE! $CRGP
Way ahead of you there! CRGP is awesome! Congrats on your divvy!
Got my CRGP divvy from Etrade today, I am one happy camper. Expect run well into pennies with many people re-investing their divvy's. Keep an eye on it!
Man brother nice work on $CRGP I had my doubts when it wouldn't lift out of the 20's but ya'll did amazing way to go!
Owoos on watch. How'd you like CRGP! Weeeeeeeee
Keep a close eye on $OWOO and $ECDP
Hurricane season is among us and looks to be a 2005 all over again. Personally I loaded up a part time staffing firm. LNTC take a look at the locations of their offices. Another one CCNI. Good luck shopping.
Man I have to agree with you I'm so happy for all who held on, can't say that I was smart enough to do the same as I had my doubts about it (seemed too good to be true) but I heard from someone today who did indeed receive their dividend. That's just awesome :) so unheard of in pennies. Congrats to you guys. Wishing ya'll continued success with it nice move shaping up, too! $CRGP
I'm still rocking with CRGP, waiting for Etrade to dole out my divvy. It made a very nice move today, I expect a lot more next week. Financials are great, maybe another dividend gets announced soon? Extremely undervalued play if they can hand out .011 per share dividend for everyone holding through 8/18. Closed today at .0045, nice move off the bottom. It took long enough, but the divvy more than makes up for it! Holding tight!
Good evening Papa Bear :) hope you are well! Ready to close out the week and head on in to another great weekend!
Bought some $EPAZ $0.0004 proceeding with caution but could be ready for a nice little pop definitely oversold with RSI of 24
Awesome brother...yep next week should get exciting, very much looking forward to Monday and getting things started...until then, cheers to the weekend! $THNS
Yep, I got in THNS also @25s...next week we should have a bit of a run. GLTA.
Added $THNS on dip @ $0.0025 should bounce nicely
Still time for folks to get in - as long as they slap the ask.
Beautiful man $CRGP could be a real monster!
It really looks like there's a possibility that this can go back to multi pennies if this buying continues. They've already bought another 18, 500, 000 shares that they haven't quite retired yet.
That $1.5m to buy back shares means they could easily buy up the remaining shares in the trading float.
I spoke to the Attorney or record yesterday who said that when he certifies a company's account he has to see their bank statements to prove they've got the money in the bank that they say they have!
Followers
|
20
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
572
|
Created
|
07/14/15
|
Type
|
Premium
|
Moderator TarHeelTrades | |||
Assistants |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |